spacer
home > ict > autumn 2017 > technological takeover
PUBLICATIONS
International Clinical Trials

Technological Takeover

A few simple ideas offer a new way of looking at patient reported outcomes (PROs), the healthcare industryís term for any data collected on the status of a patientís health condition that come directly from the patient. The first is that technology today has great potential to become organic and integral to a patientís physical state and lifestyle. Another is that, through this technology, information can stream directly from a patient in real time and convey health information that is comprehensive, reliable and accurate. This progression of a patientís narrative, from the patientís own senses to the patientís sensor that does the talking, promises to reshape many sectors of healthcare, from precision medicine to clinical trials.

PROs as We Know Them

Asking patients to assess their own sense of wellbeing has been a method used for many years to gather health information that can influence medical treatments and their regulatory approvals. Nonetheless, the data, such as severity of pain, nausea or sleep deprivation, can be highly variable based on individual perceptions Ė personal filters, so to speak. Factors that contribute to patient accuracy regarding adherence to treatment regimens and factors in patient recall, such as state-of-mind during an event and the time elapsed since, play a significant role in the reliability of patient-reported information. This, in turn, can make data highly subjective and less relevant than measures based on technological objectivity.

In the healthcare industry, there are standardised means of gauging the characteristics of a patientís experience. In clinical practice and research, patient-reported symptoms and quality of life issues related to disease progression or drug intake have traditionally been tracked using validated questionnaires. These assessments may be general and applicable to many diseases and interventions, or they may be specific to a single diagnosis or treatment. Further, different research institutions have developed their own validated questionnaires. Using such methods supports an approach to medical care that values the dimensions of a patient experience that have been technically unmeasurable.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Jeff Beeler, Vice President of Product Innovation for IBM Clinical Development from Watson HealthTM, has over 15 years of experience in the clinical trials industry, including clinical research organisations. With expertise in SAS programming, data management and developing systems for effectively conducting clinical studies, Jeff is attuned to the challenges of bringing therapies to market and passionate about reducing barriers within clinical research.

Alysa Lesemann, Senior Writer at IBM Clinical Development from Watson HealthTM, has worked for over a decade to advance medical and science research in academia, industry and government, coordinating research programmes and writing content for organisations such as the University of North Carolina, RTI International and the National Cancer Institute. With a background in the performing arts and literature and an interest in expressing technical and personal narrative through a range of media, Alysa also holds a doctorate in biophysics from The Johns Hopkins University, US.

spacer
Jeff Beeler
spacer
spacer
spacer
Alysa Lesemann
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

rfxcel Covers the Cost of EMVO Onboarding Fees

May 23, 2018 - San Ramon, CA Ė rfxcel Corporation, a technically certified Gateway Provider for the European Medicines Verification Organisation (EMVO) announced today that it will pay the cost of statutory fees payable to EMVO* for all manufacturers (Marketing Authorisation Holders, MAHs) which select rfxcel as their Gateway Provider before June 15th 2018.
More info >>

White Papers

Clinical Trials in Ukraine: Orange Paper Overview and 1st Half Year 2014

Synergy Research Group

The Orange Paper is an analytical report about the clinical trials market in Russia, published quarterly by the contract research organization Synergy Research Group. The first edition of Orange Paper was released in 2006, and at the moment 31 issues have already published. Now, thanks to Synergy Group Ukraine, obtaining information about the market of clinical trials in Ukraine has become possible. In Ukraine, during the period from 1996 to 2013, applicants had obtained 3,864 positive conclusions about the possibility of conducting clinical trials of drugs, both for domestic and foreign manufacturers, including conduct of multinational multi-center clinical trials (hereinafter Ė MMCTs)
More info >>

 
Industry Events

SMiís 5th Molecular Diagnostics Conference

9-11 July 2018, Holiday Inn Kensington Forum, London, UK

SMi is proud to announce their 5th Molecular Diagnostics conference. The event will take place in central London on Monday 9th and Tuesday 10th July 2018, along with two half-day post-conference workshops taking place on Wednesday 11th July 2018
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement